Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
CONCLUSIONS: Longer-term exposure to canagliflozin as monotherapy or in combination with other agents was generally well tolerated in patients with T2DM.
PMID: 27977934 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Glimepiride | Heart | Insulin | Invokana | Januvia | Research | SGLT2 Inhibitors | Study | Urinary Tract Infections | Urology & Nephrology